Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
In the wake of the deal's completion, Achilles also rvealed plans to reduce its employee headcount and trim its Board of Directors, while staying compliant with Nasdaq and SEC requirements.Achilles Therapeutics plc (NASDAQ:ACHL) shares are trading higher on Tuesday after the company announced a $12 million deal with AstraZeneca PLC (NASDAQ:AZN) and plans to cut jobs.
阿基里斯治療公司（納斯達克：ACHL）股價在週二上漲，此前該公司宣佈與阿斯利康（納斯達克：AZN）達成1200萬的交易，並計劃裁員。
The agreement involves the transfer of the commercial license for data and tumor samples from Achilles' TRACERx Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca.
該協議涉及阿基里斯將其TRACERx非小細胞肺癌（NSCLC）研究的數據和腫瘤樣本的商業許可證轉讓給阿斯利康。
The million deal signals the conclusion of Achilles' strategic review, which was announced in September 2024.
這筆交易的達成標誌着阿基里斯的戰略評估結束，該評估於2024年9月宣佈。
In the wake of the deal's completion, Achilles also rvealed plans to reduce its employee headcount and trim its Board of Directors, while staying compliant with Nasdaq and SEC requirements.
在交易完成後，阿基里斯還透露將裁減員工人數並縮減董事會規模，同時保持與納斯達克和SEC的合規性。
"Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors, while remaining compliant with Nasdaq and SEC requirements," the company noted.
公司指出："阿基里斯現在計劃採取更多措施，包括進一步減少員工人數和縮小董事會規模，同時保持與納斯達克和SEC的合規性。"
Also Read: American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back
另請閱讀：美國航空解除聖誕前夕停飛，股價回升
TRACERx, a study led by Professor Charles Swanton at University College London (UCL), has collected extensive genetic data from over 3,200 tumor samples from more than 800 lung cancer patients.
TRACERx是由倫敦大學學院（UCL）的查爾斯·斯萬頓教授領導的一項研究，已從800多名肺癌患者的3200多個腫瘤樣本中收集了廣泛的遺傳數據。
This multi-region, multi-time-point sequencing offers deep insights into cancer evolution and treatment responses.
這種多區域、多時間點的測序提供了對癌症演變和治療反應的深入見解。
As part of the deal, AstraZeneca will also take over Achilles' Material Acquisition Platform (MAP), which houses tumor samples and data collected from nearly 300 cancer patients across various solid tumor indications such as lung, melanoma and breast cancer.
作爲交易的一部分，阿斯利康還將接管阿基里斯的材料採購平台（MAP），該平台存儲着從近300名癌症患者收集的腫瘤樣本和數據，這些患者的癌症類型包括肺癌、黑色素瘤和乳腺癌等各種實體腫瘤。
"We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets," said Dr. Iraj Ali, CEO of Achilles Therapeutics.
阿基里斯治療公司的首席執行官伊拉吉·阿里博士表示：「我們很高興，作爲腫瘤學領域的領導者，阿斯利康認可我們TRACERx和MAP資產的科學價值。」
The company believes these assets have significant potential to aid in developing improved cancer therapies.
該公司認爲這些資產有很大的潛力可以幫助開發改善癌症治療的方法。
Price Action: ACHL shares are trading higher by 7.01% to $1.050 at last check Tuesday.
價格走勢：截至週二最後檢查，ACHL股票上漲了7.01%，成交價爲1.050美元。
- MicroStrategy Sinks After Nasdaq 100 Inclusion: Bitcoin Bet Under Fire?
- MicroStrategy在納斯達克100納入後大跌：比特幣投資受到質疑？
Photo by Johaehn from Pixabay
攝影來自Pixabay的Johaehn
譯文內容由第三人軟體翻譯。
